

**OPDUALAG**  
**(nivolumab and relatlimab-rmbw)**

## **Pre - PA Allowance**

None

---

## **Prior-Approval Requirements**

**Age** 12 years of age or older

### **Diagnosis**

Patient must have the following:

1. Unresectable or metastatic melanoma
  - a. Age 12-17 **only**: patient weight  $\geq$  40 kg

**AND ALL** of the following:

- a. Prescriber agrees to monitor liver enzymes, creatinine, and thyroid function at baseline and periodically during treatment
- b. Prescriber agrees to discontinue treatment for any immune mediated adverse reaction (encephalitis, nephritis, rash, decreased renal function, and endocrinopathies) or disease progression
- c. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Opdualag and for 5 months after the last dose

## **Prior - Approval Limits**

**Quantity** 6 single-dose vials every 84 days

**Duration** 12 months

---

## **Prior – Approval *Renewal* Requirements**

**Age** 12 years of age or older

### **Diagnosis**

Patient must have the following:

1. Unresectable or metastatic melanoma
  - a. Age 12-17 **only**: patient weight  $\geq$  40 kg



**BlueCross  
BlueShield**

Federal Employee Program.

**OPDUALAG  
(nivolumab and relatlimab-rmbw)**

**AND ALL** of the following:

- a. **NO** disease progression or unacceptable toxicity
- b. Prescriber agrees to monitor liver enzymes, creatinine, and thyroid function periodically during treatment
- c. Prescriber agrees to discontinue treatment for any immune mediated adverse reaction (encephalitis, nephritis, rash, decreased renal function, and endocrinopathies) or disease progression
- d. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Opdualag and for 5 months after the last dose

**Prior - Approval *Renewal* Limits**

Same as above